Molecular Landscape and Treatment Options for Patients with Metastatic Colorectal Cancer.

about

Molecular Landscape and Treatment Options for Patients with Metastatic Colorectal Cancer.

Item

http://www.wikidata.org/entity/Q45989066

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

Molecular Landscape and Treatment Options for Patients with Metastatic Colorectal Cancer.

@en

Molecular Landscape and Treatment Options for Patients with Metastatic Colorectal Cancer.

@nl

type

Item

label

Molecular Landscape and Treatment Options for Patients with Metastatic Colorectal Cancer.

@en

Molecular Landscape and Treatment Options for Patients with Metastatic Colorectal Cancer.

@nl

prefLabel

Molecular Landscape and Treatment Options for Patients with Metastatic Colorectal Cancer.

@en

Molecular Landscape and Treatment Options for Patients with Metastatic Colorectal Cancer.

@nl

P1476

Molecular Landscape and Treatment Options for Patients with Metastatic Colorectal Cancer.

@en

P2093

Wu Zhang

http://www.w3.org/2001/XMLSchema#string

Yuji Miyamoto

http://www.w3.org/2001/XMLSchema#string

P2860

Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer

Comprehensive molecular characterization of human colon and rectal cancer

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.

Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.

Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer.

The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.

P2888

s13193-016-0543-z

P304

580-590

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1007/S13193-016-0543-Z

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Heinz-Josef Lenz

P577

2016-07-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1053734773

http://www.w3.org/2001/XMLSchema#string

P698

29203992

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

5705494

http://www.w3.org/2001/XMLSchema#string